Core F: Biomarker/Neuroimaging Core

摘要-生物标志物/神经成像核心 在拉什阿尔茨海默病研究中提出的生物标志物/神经成像核心的总体目标 中心（拉什ADRC）是建立一个资源的神经成像数据的参与者拉什ADRC和 辅助研究，并提供神经影像学专业知识，以促进高质量，尖端，外部资助 研究重点是从正常衰老到轻度认知障碍（MCI）的早期阶段的过渡 阿尔茨海默氏症（AD）和其他痴呆症的研究。具体而言，生物标志物/神经成像核心将整合 高质量、多模态、纵向体内和体外脑磁共振成像（MRI）数据， 新收集的正电子发射断层扫描（PET）数据，从拉什ADRC的参与者，并分别 资助的研究，所有基于最先进的，统一的数据采集协议。生物标志物/神经影像学 Core将对体内和体外MRI数据进行全面质量检查和详细处理， 数据库生成丰富的输出宏观结构，微观结构，化学和功能的大脑 特征和新的分类器的血管和神经退行性过程中老年人的大脑。 PET数据的质量检查和处理将由SCAN（标准化集中 阿尔茨海默氏症和相关痴呆神经影像学）。Rush ADRC的生物标志物/神经成像核心将 将所有脑部MRI和PET数据和处理结果广泛分发给研究人员， 拉什ADRC，并将提供神经影像学专业知识，支持研究工作，在正常老化，认知 衰退、轻度认知障碍、AD和相关痴呆。申报的生物标志物/神经影像学核心 将建立在拉什ADRC的优势，包括A）纵向临床评估的人谁登记 无痴呆，B）纵向生前生物流体收集，和C）死后生物样本收集 很多人没有痴呆症生物标志物/神经影像学的贡献 核心将刺激研究，A）开发新的基于MRI的年龄相关神经病理学分类器，B） 阐明支持认知和运动健康或导致衰退的大脑机制，C）评估 风险因素对大脑的影响，D）将神经影像学与多层次组学联系起来，E）支持发展和 基于外周血和视网膜成像的新生物标志物的验证，和F）证实了 认知老化相关结果的种族/民族差异中的各种大脑特征。

ABSTRACT – BIOMARKER/NEUROIMAGING CORE The overall goal of the proposed Biomarker/Neuroimaging Core in the Rush Alzheimer’s Disease Research Center (Rush ADRC) is to build a resource of neuroimaging data on participants of the Rush ADRC and ancillary studies, and provide neuroimaging expertise to facilitate high quality, cutting edge, externally funded research focusing on the transition from normal aging to mild cognitive impairment (MCI) to the earliest stages of Alzheimer’s disease (AD) and other dementias. Specifically, the Biomarker/Neuroimaging Core will integrate high quality, multi-modal, longitudinal in-vivo and ex-vivo brain magnetic resonance imaging (MRI) data and newly collected positron emission tomography (PET) data from participants of the Rush ADRC and separately funded studies, all based on state-of-the-art, uniform data acquisition protocols. The Biomarker/Neuroimaging Core will perform thorough quality checks and detailed processing of the in-vivo and ex-vivo MRI data in the database to generate rich output on macro-structural, micro-structural, chemical, and functional brain characteristics and on novel classifiers of vascular and neurodegenerative processes in the older adult brain. Quality checks and processing of the PET data will be conducted by SCAN (Standardized Centralized Alzheimer’s and Related Dementias Neuroimaging). The Biomarker/Neuroimaging Core of the Rush ADRC will widely distribute all brain MRI and PET data and processing results to investigators within and outside of the Rush ADRC, and will provide neuroimaging expertise in support of research efforts in normal aging, cognitive decline, mild cognitive impairment, AD and related dementias. The proposed Biomarker/Neuroimaging Core will build upon strengths of the Rush ADRC including A) longitudinal clinical assessment of persons who enroll without dementia, B) longitudinal ante-mortem biofluid collection, and C) post-mortem biospecimen collection from large numbers of persons, many without dementia. The contributions of the Biomarker/Neuroimaging Core will stimulate research that A) develops novel MRI-based classifiers of age-related neuropathologies, B) elucidates brain mechanisms supporting cognitive and motor health or leading to decline, C) evaluates the effects of risk factors on the brain, D) links neuroimaging to multi-level omics, E) supports the development and validation of novel biomarkers based on peripheral blood and retinal imaging, and F) ascertains the role of various brain characteristics in racial/ethnic disparities of cognitive aging related outcomes.